



Date: February 5, 2015

**ELN Recommendation Meeting
San Francisco, United States
December 4, 2014**

Organizer: Prof. Dr. Andreas Hochhaus

Summary

The ELN workpackage 4 (chronic myeloid leukemia) releases recommendations for CML in journals (Baccarani Blood 2006, JCO 2009, and Blood 2013), as pocket cards and on the ELN website. The recommendations include definitions of failure, suboptimal response, warnings and optimal response (http://www.leukemianet.org/content/leukemias/cml/recommendations/index_eng.html).

It is expected to provide new recommendations in January 2016. For this purpose about 32 members of the ELN will discuss the upcoming recommendations. The session is by invitation only and confidential.

Scientific content of and discussion at the Symposium

Description	Topics	Discussion notes
Introduction	Citations, Panel composition and topics of previous recommendations	Summarized by A. Hochhaus
Aims	Methods for new recommendations	<ul style="list-style-type: none">• In previous recommendations besides of peer-reviewed papers ASH and EHA abstracts were permitted• Citations up to 6/2012 were included in the most recent version of 2013
	Format	<ul style="list-style-type: none">• Possible Journals could be Leukemia or Blood• The new Lancet of hematology was rejected by majority
Considered topics	Aim of therapy: Treatment free remission (TFR) vs. overall survival (OS)	<ul style="list-style-type: none">• Important to consider what to do with pts. Not eligible for TFR• Personalized approach especially for first line treatment• Correct dosages currently used?
	AP/BP definition	<ul style="list-style-type: none">• Proposal of M. Baccarani• initial vs. secondary AP (under therapy)
	Initial pt. management	<ul style="list-style-type: none">• Proposal by A. Hochhaus to add recommendations on management of therapy during first weeks



		<ul style="list-style-type: none"> • Cooperation with expert centers
	Definition of response (table)	<ul style="list-style-type: none"> • Should we stay with the warning category? • Alternative could be used optimal vs. non-optimal • Controversial discussion as some panel members think this category led to uncertainties in management whether others believe it is more clear
	Definition of molecular response	<ul style="list-style-type: none"> • Updated EUTOS definitions to avoid arbitrary results for e.g. in definition of MR4.5
	QoL	<ul style="list-style-type: none"> • Only short paragraph in current version
	Discontinuation strategies	<ul style="list-style-type: none"> • Important as new data emerging and stopping performed outside of trials
	Pregnancy	<ul style="list-style-type: none"> • At the moment no new data???
	Treatment of Failure	<ul style="list-style-type: none"> • New data especially on ponatinib should be added
	Treatment of advanced diseases	<ul style="list-style-type: none"> • Probably not to mention as there are nearly no news and already several comprehensive reviews available that could be cited
	Role of allo-SCT	<ul style="list-style-type: none"> • Should be updated
	CML in children	<ul style="list-style-type: none"> • It was agreed not to add to this recommendations as pediatricians are going to publish their own recommendations and not to add new panel members
Next steps	1) Questionnaire 2) Next meetings	<ul style="list-style-type: none"> • According to the discussed topics a questionnaire will be send around by A. Hochhaus • EHA meeting, Vienna, Thursday 11.6.2015 • ESH meeting, Estoril 1.-4.10.2015 • ASH meeting, Orlando, Dec 2015

Assessment of results and impact of the Symposium on the future direction of the field

New recommendations will have major impact on treatment decision in CML.

Final Program

1. Introduction

a. Citations of former ELN recommendations



- b. Panel composition
 - c. Topics discussed in previous issues
 - 2. Aims
 - a. Methods for new recommendations
 - b. Format
 - 3. Considered topics for new update
 - 4. Next steps
-